New Frontiers in the French Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape

New Frontiers in the French Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape

Category : Diagnostic and Biotech
May  2014 


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Complete report $6,100.  DataPack (test volumes, sales forecasts, supplier shares) $3,950.

New Frontiers in the French Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new study of the major business opportunities emerging in the French clinical chemistry and immunodiagnostic markets during the next five years.  The report explores future trends in the French market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.

Rationale

The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.  This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

France Market Overview

- Estimates of facilities performing clinical chemistry 
and immunodiagnostic tests.

- Test volume and sales projections.

Strategic Recommendations

- New product development opportunities
with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Market Segmentation Analysis

- Comprehensive review of the market
dynamics, trends, structure, size, growth,
and key suppliers.

- Test volume and sales forecasts for over 100 clinical chemistry, 
TDM, endocrine, cancer, immunoprotein and abused drug assays,
by market segment:
     
     ° Hospitals
     ° Commercial/Private Laboratories

Tests Analyzed in the Report

Routine Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total, 
BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose, HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, 
Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, 
Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake,  Free T3, T4, Free T4, TBG, Testosterone,
Thyroglobulin Ab,  TPO Ab, TSH.

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), 
Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,
PAP, PSA, Thyroglobulin, Vitamin B-12.

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,
Immunofixation, Prealbumin, Protein Electrophoresis.

Drugs of Abuse

Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP), 
Propoxyphene, Tricyclic Antidepressants.

Current and Emerging Products

- Analysis of current and emerging clinical chemistry 
and immunodiagnostic tests.

- Review of current instrumentation technologies, and feature comparison 
of high-, medium-, and low-volume/POC analyzers.

Technology Review

- Assessment of current and emerging
technologies, and their potential  market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Competitive Assessments

- Strategic assessments of major suppliers and 
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D. 

- The companies analyzed in the report include: 

   - Abbott Laboratories
   - AdnaGen
   - Agilent Technologies          
   - Beckman Coulter/Danaher
   - Biomedical Diagnostics
   - BioMerieux
   - Bio-Rad              
   - DiaSorin
   - Eiken
   - Fujirebio/Innogenetics
   - Instrumentation Laboratory
   - Kyowa Medex
   - Matritech/Alere
   - Ortho-Clinical Diagnostics
   - Quest Diagnostics
   - Roche
   - Siemens
   - Sysmex
   - Thermo Fisher
   - Tosoh
   - Wako
   - Wallac/PE

Contains 542 pages and 104 tables

image
Can't read the image ? refresh here.


Enquiry Before Buy
image
Can´t read the image ? refresh here.